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Abstract: By today, in our business environment, mostly based on innovation, the 
potential opportunities in the pharmaceutical sector and impact of these to the national 
economic trends has a determining significance. This latter requires the examination of 
the impact of research and development activity as the most important factor to the 
profitability of two selected regional market leader pharma companies and presentation 
of how these groups handle their high operating risks which resulting from these 
investments. National and international importance of the pharmaceutical industry defined 
by not only the prominent role of application of the biochemical academic research, but 
the humanitarian concerns which increasingly appreciating in the global context. In the 
developing and overpopulated countries the risks of become massive epidemics arisen 
from the emergence viruses which mutating quickly and in increasingly complex forms 
has risen due to the scientist discoveries and more modernize preventive procedures. 
These facts – in view of growing efficient immune substances developing procedures – 
are stronger pressure on the industrial actors, with this affecting the profitability of future 
operations. The farming specificities and their role can be illustrated well by comparing 
the activities of the Central European market-leader Richter and the world-renowned 
Swiss Novartis which ranked number two in sales with approximately 47 billion dollar 
among the world-wide pharma groups in 2010. Since the comparable figures based on 
IFRS, it must be also mention that how the international accountant standards display 
these management areas. Among the examined factors, the pharma R&D activity had the 
highest impact on the long-term firming both individually and in comparison, but the 
different of the financial strategy and accounting policy as a kind of asset of risk 
management had no negligible. My analysis is mostly theoretical and based on 
quantitative methods. All the pharma companies cross-border can use my results, 
because they show that why need to pay more attention in this sector to the R&D in order 
to preserve their market position, thus to ensure multilaterally the prevention of the 
diseases. 
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1. Sectoral outlook 
 
The ability of companies to hold themselves in the globalized market economy, the 
maintenance and improvement of its competitiveness, furthermore inform the foreign 
investors, and utilization of the different opportunities of financing such as cross-border 
type of emerging challenges in some innovation-intensive sectors make it necessary 
strategic-level management of those as well as the spatial and temporal comparison of 
activity of concerned companies. In the most capital-intensive pharmaceutical industry – 
in addition to its stable position in the short term has not undermined even by the impact 
of the 2008-2009’s financial crisis – the extent of the R&D and innovation investment – 
even in 2011 – exceeded all same values recognised in another industry. The profitability 
of pharmaceutical sector is determined by the public health and income status of regions 
population, the social and innovation policy of the state as the price and market conditions 
which primarily affect the demand trends. Internationally, the most favourable prospects 
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are attributed to this sector since in this area proceed of technological changes relatively 
rapid due to the introduction of the new medicinal preparations. Partly because of this, the 
health budget expenditures have increased dramatically worldwide owing to the impact of 
ever growing costs pressure (FRANK–CHEE-RUEY, 2007.). The pharmaceutical industry 
is under growing pressure from a range of environmental issues, including major losses 
of revenue owing to patent expirations, increasingly cost-constrained healthcare systems 
and more demanding regulatory requirements (STEPHEN et al). 
 
Table 1: Key financial data of the three major segments of the pharmaceutical industry 
internationally (2012). Revenue = 100% 
Segment Gross profit 
Operating 
income 
Net 
income R&D 
R&D / 
Revenues* 
Major Drug 
Manufacturers 70% 21% 17.0% 15% 0.2% 
Biotechnology 
Manufacturers 80% 22% 15.2% 22% -5.7% 
Generics Drug 
Manufacturers 68% 16% 11.3% 9% 0.6% 
Overall Industry 71% 21% 16.1% 15% 0.56% 
*it shows, how R&D change with every additional bnUSD in net sales. 
Source: Business Data Insight (I1), 2013. 
 
Industry margins in the sector are high enough and as it can see the splits below, the 
Major Drug Manufacturers segment is the most profitable one, which also indicates 17% 
net margin as a result of the exploitation of blockbuster drugs, which brings in high cash 
flows (FRANCESCO, 2013). The principle of economy of scale prevails: generally 
speaking that overall in the industry, the R&D expenses decrease with the company 
getting bigger in owing to mostly the fact that many activities are shared and further 
efficiencies found (FRANCESCO, 2013). According THOMAS (2007) the pharmaceutical 
market can be divided three sections based on the type of costumers: patients, 
institutional buyers (hospitals, pharmacies) and the government. In the traditional retail 
market the price of prescribed medicinal products is paid out by the consumers and/or the 
social insurance, so this segment is the less price-sensitive. Although the medical 
institutions may use certain products limited by the law, these able to cause large demand 
for some preparations via the freedom of the drug contest, so their strong market position 
and price sensitivity is also higher than the retail consumers, which has been a key factor 
in terms of profitability for manufacturers.  
 
2. Material and method 
 
At the analysis of impact of R&D and other factors I demonstrated the results by the 
method of sensitivity analysis in such a way that I deduced the necessary conclusions 
resulting from the deviation between the trends of actual indicators and the same results 
changed next to the ratio or items of the Novartis serving as a benchmark while being all 
other factors unchanged. I used IFRS reports those serving a basis of comparison for the 
secondary data collection. 
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3. Comparative analysis of the profitability of the Richter and Novartis 
 
It is necessary to underline those financial indicates to the exam of the profitability which 
reflects that how effectively provide its result through the managemant of scarce 
resources (LUC – TARNÓCZI, 1995). These include the return on sales (ROS), assets 
(ROA) and equity (ROE). 
 
 
Figure 1: Comparison of the three profitability rates (2009-2012)  
Source: own compilation. 
The ROS after tax in 2009 and 2011 are almost equal in the two company groups, in turn 
the index of Richter fell to a lower level in 2012 at the same time when increased the 
borrowed loan portfolio. The Richter’s ROA after tax in 2011 approached to the same 
index of the Novartis partly due to the total asset turnover rate, on the other hand the 
decreasing returns of sale which effect has manifested to the return on equity: the 
Hungarian factory was able to provide more capital increase for its owners only in 2010. 
Because of the positive impact of the equity multiplier, the ROE indicators in both cases 
were higher than ROA rates: the Novartis could multiply its equity approximately twice as 
good as the Richter the years under review. Later, in the comparison of effects, I use pre-
tax ROS and ROA in my analysis in order to simplification, as comparison made it difficult 
by several factors: these include the different tax environment, the marginal effect of 
income taxes on basic tendency and the consolidated type of reports. 
 
3.1. The impact of the pharma R&D and innovation investments 
 
The most capital-intensive type of the pharma industry is explained by the R&D 
expenditures and the related investments which are significant part of all the expenses 
related to the manufacturing activity. Furthermore, the associated potential government 
grants and tender sources also have to be considered as revenue-raising items until 
marketing of the newly developed products, from the time when it also contributes to the 
revenue growth so it plays an important role in determine of the result. Requirements for 
the presentation of R&D expenses are outlined under IAS 38, which enable that the 
accounting treatment of intangible assets and in case of accomplish of internationally valid 
conditions identification and account of those. IAS 38 applies to the advertising and start-
up as well as the R&D – in accordance with standard research is original and planned 
investigation, that will contribute to a new scientific or technical knowledge or theoretical 
knowledge to obtain it: for instance in this sector it could be tests aimed at obtaining new 
knowledge to develop a new vaccine. Development can be attributed to the results of 
0.0%5.0%10.0%15.0%20.0%25.0% 2009 2010 2011 2012 Novartis - ROSNovartis - ROANovartis - ROERichter - ROSRichter - ROARichter - ROE
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research or the knowledge gained in utilizing in order to design new or substantially 
improved materials, devices, production of products, processes and services, even in the 
marketing of products and use prior to the start (ROBERT, 2009). If an entity cannot be 
clearly separated the research phase of an internal project to creating an intangible asset 
from the the development phase, so the company can also manage its cost such a way 
as if those only would have been incurred in the research phase (KAMAL, 2005). 
Generally, the R&D projects – including the basic and applied research – are always 
embedded in the larger scope of innovation management (SEBASTIAN et al, 2009). 
Both Novartis and Richter has invested several million forint and dollar into the R&D field 
and various development projects – significant part of connected costs appear outside the 
expenditures, also among the intangible assets if those meets requirements of IAS 38. As 
regards the investment policy, although within the estate of Novartis the share of fixed 
assets approached the eighty percent in the latest years – until then with the exception of 
the year 2010, when Novartis could reach remarkable product portfolio growth by the 
acquisition of Alcon – in the case of Richter there was greater relative role of the producers 
and developers investments. This can be explained by the difference which can observe 
in the investment policy that the Swiss pharma producer placed more emphasis on 
acquisition of financial instruments, in spite of this the Hungarian company focused on 
graduating expansion of existing generating capacities. Consequently in 2010, during the 
acquisition of Preglem S.A., a new preparation, the ESMYA intangible asset and goodwill 
has been recorded, then, from 2011 the complete of the plant building – specialised on 
biotechnological mammalian cell method and related technological system installation – 
carried out as a Greenfield investment in Debrecen has already contributed by 
considerable extent to the growth of the fixed assets in the following year. 
Figure 2: The share of R&D investments and costs turned to the development projects 
within all the R&D expenses and the share of the latter value within the revenue 
Source: own compilation. 
Due to the acquisitions and the Greenfield investment were able to increase its fixed 
assets substantially and inside of this, the extent of intangible assets for both of two 
companies – only the consolidation of Alcon caused nearly 18 billion USD goodwill growth 
for Novartis. One part of the costs incurred in connection with research and development 
activities consist of the personnel (related to employees in group headquarters and 
locations those specialized in vaccine production) and other material expenses, the 
remaining part of these make up from the acquisition of material and intangible assets – 
in the pharma sector mostly computer softwares which help to study of the different 
molecular structures modelling – these are made up from research and development 
0.00%2.00%4.00%6.00%8.00%10.00%12.00%14.00%16.00%18.00% 2009 2010 2011 2012 2009 2010 2011 2012NOVARTIS RICHTER Other R&Dexpensescompared torevenueR&D investmentsand costs ofdevelopmentprojects comparedto revenue
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investments. The deviation between also the share of the latter values within the net sales 
(Figure 2), also all the operating and marketing costs of two companies decreased 
considerably by 2012, primarily due to the investments of Richter in that field. While the 
Novartis was turning 16-18% of its net sales to product development from 2009 to 2012, 
its Hungarian competitor could surpass the 10 percent only the last examined year during 
the same time due to the fact that early this year the European Commission has granted 
the marketing authorization of the 5 mg ESMYA, so Richter could embark clinical studies 
concerning the Pill in the third quarter of 2012 in order to facilitate the durable cure that is 
surgical interference-free and resulting the reduction of benign tumours. Besides of this 
the earlier noted biotech plant of Richter was also handed over that can keep R&D 
expenses above level of 10 percent sustainably as a result of industrial production of more 
complex protein-based preparations – thus the Hungarian pharma company can reach 
value that indicated at Novartis which stagnated above 16%. As regard the share of R&D 
expenses within all the operating costs, at none of two companies can already show 
greater fluctuations: while there were identical trends until 2011, in the following year the 
role of concerned kind of cost increased by 3% at Richter opposite the Novartis on effect 
of handed biotech plant. 
At determining of the impact of R&D activity on profitability only the related expenses and 
the net sales revenue surplus associated with marketing of the successfully developed 
products were considered by me. Nevertheless I did not calculate with the tax benefits, 
post-tax credit and other benefit provided connection with the research activities has been 
caused by that I started from the earning before tax at the evaluating of the profitability 
indicators – for the reason mentioned above. Therefore, the state grants which received 
to compensate costs similarly cannot be taken into account in the calculation, because, 
although – unlike the Richter – the Novartis was obtained different amount of state grants 
after investments and capacity buildings carried out in the USA to purchase material 
assets – those help to improve new vaccines – and to build other sites in the framework 
of the American government grant contracts, the effect of these items on earning before 
tax offset by the costs of purchases which financed by the grants (the accrued grants 
released among incomes in proportion with the depreciation that deducted from the cost 
of the purchased assets every year). So only the effect of R&D’s direct and indirect costs 
may be considered until the realize of revenue growth that is arising from sale of 
preparations which is newly placed on the market as a result of proving successful 
experimental development projects, clinical trials and these are under patent law 
protection.  
 
 
Figure 3: The effect of R&D activities on the return on sales 
0.0%5.0%10.0%15.0%20.0%25.0%30.0%35.0%40.0% 2009 2010 2011 2012 Novartis - Original ROSbefore taxesNovartis - CalculatedROS before taxeswithout R&DRichter - Original ROSbefore taxesRichter - CalculatedROS before taxeswithout R&D
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Source: own compilation. 
Light of the foregoing, it could be mostly illustrate the impact of R&D in the difference of 
the indicators, if we examine the changes of the rates for both companies on the condition 
that the period under view those did not carry out this type of activity. If the result items 
are adjusted by disregard of the showed net sales of the newly introduced products 
manufactured exclusively during the examined period, furthermore the accounted R&D 
expenses in each year, then it can be observe a bigger difference than between the 
original ROS values. It can be identify from tendencies that – against Novartis – the ROS 
of Richter – which group primarily specialized in developing of gynaecological 
preparations – without R&D would higher by 5-7 percent than that in fact. This can be 
explained by funds of Richter turned to the development projects paid off less than 
expected, namely the later years these were not associated with such revenue growth 
that equal or higher than the magnitude of earlier investments, in addition the results of 
the large projects started in 2012 can only occur naturally in the coming years. At Novartis 
sales revenue of the newly marketed preparations enhanced the Group’s total net sales 
by an average of 26 percent between 2010 and 2012, which contribute to its falling trend. 
As a result the lack of this would have completely neutralized the solvency advantages 
from possible saving of costs connected with developments. It should mention even tax 
effect of R&D on the earning after taxation, because this item has been greatly influenced 
by the tax benefits those are available after research activities and different from country 
to country, possibilities of tax credit, furthermore the connected costs – particularly in the 
case of Richter can be considered relevant factors – accounted as tax base reducing 
items at the corporate tax base and – from 2010 – at the local tax base which became 
possible by the Act C of 1990 on Local Taxes and the Act LXXXI of 1996 on Corporation 
Tax and Dividend Tax. 
 
Table 2: Calculated amounts of all the tax saving coming from R&D in million EUR 
Tax Saving (million EUR) 2009 2010 2011 2012 
Novartis Group 257.7 282.7 61.2 138.9 
Richter Group 14.9 16.6 17.6 15.7 
Source: Based on IFRS reports of Richter and Novartis, furthermore own calculation at 
Richter. 
 
Under recent facts partly, the company could available developing tax benefit in present 
value of about 100 million Ft in the case of investment projects serving basic and applied 
research or experimental development. On the other hand Richter could ensure itself 10 
years from the installation 100% corporate tax saving with the productive investment of 
value more than 3 billion Ft after the results of the parent company in Hungary. The Table 
2 included all the tax saving validated by the support system exclusively resulting from 
the R&D and recalculated to euro in order to comparability. Extraordinary tax benefit of 
the Novartis – against Richter – results from its institutional network that considered wide 
and strength internationally too. All in all, Novartis can distribute its new formulations on 
markets where demands are less price-sensitive but high solvent, so it can ensure the 
return on investment of product developments more successfully than Richter.  
 
3.2. Managing of risks arising from R&D by financial and accounting policy 
 
At comparing of profitability the effect of financial strategies of both companies must be 
taken into account as those determine the structure of asset finance and influence the all 
asset rotation speed that multiplication factor between the ROS and ROA. As a test of 
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this, on the one hand we seek the answer to that the assets serving the activity and 
ranking according to terms of liquidity financed by which structure and origin of liabilities, 
furthermore which corporate financing policy can observe behind of this in the long run, 
on the other hand in what extent the cost of acquisition of foreign resources affects the 
results, so the profitability. Two indicators those expressing the mostly the asset financing 
are the coverage of non-current assets and the rotation speed of the current assets 
decreased by short-term liabilities, namely the net working capital. The results of the 
previous indicator (from 101% to 123% at Novartis and from 275% to 433% at Richter) 
clarify that the non-current assets of both producers are covered fully by the permanently 
available resources, although the values recorded at Richter exceeds third times the data 
of its Swiss competitor which already refers that Novartis – against more conservative and 
prudent financial strategy of Richter – use more aggressive or so-called solid policy that 
is better suited for the fit principle: its long-term working capital fixing financed by long-
term sources much lower than Richter, which allows also riskier operation in case of 
Novartis. 
 
Table 3: The ratio of net working capital within the all asset  
Source: own compilation. 
The ratio of net working capital decreased by 2011 due to the restructure performed in 
the assets that result at Richter the acquisition of Grünenthal and PregLem S.A., and the 
share purchase transactions in the Protek Group which is Russia’s largest pharmaceutical 
wholesaler, while that at Novartis the increasing non-current asset ratio owing to the 
consolidation of Alcon and the rise of equity also was not able to offset – even nor with a 
long-term borrowings. 
 
Table 4: The all asset rotation speed of Richter calculated assuming the ratio of net 
working capital of Novartis 
Denomination 2009 2010 2011 2012 
Change in the all asset rotation 
speed by modifying -0.51 -0.43 -0.46 -0.45 
Change in the ROA at Richter -9.0% -8.4% -6.9% -6.9% 
Source: own compilation. 
 
Follows from the foregoing that the continuation of market policy of Novartis for 
acquisitions intensified in 2010 was much riskier in terms of using financial strategy, as in 
the case of Richter, which was able to reserve allocated in previous years partly to cover 
of this. The high net working capital certified strong solvent position and at the same time 
ensured to pursue more flexible financial policy for both groups. As the ROA is affected 
by the all asset rotation speed so the effect of different financial strategy on ROA can also 
be illustrated if the ratio of average net working capital of Richter modified to the same 
index value of Novartis in such a way that the size of total assets and the net working 
capital rotation speed is left unchanged and we solely wish to express the net sales in 
knowledge of the amended variable – assuming that the modifying net working capital is 
also managed effectively the same away than otherwise by Richter. As a result, the 
received new net sales divided by the unchanged average all asset, the new all asset 
Denomination 2009 2010 2011 2012 
Net working 
capital / The all 
asset (%) 
Novartis 14.9% 1.6% 0.8% 3.2% 
Richter 47.7% 30.4% 29.7% 35.4% 
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rotation speed, thus the ROA would much lower if Richter continued as the same financial 
policy as the Swiss producer. From this it can define that the different ratio of current 
assets financed by permanent sources significantly contributed to the fact that Richter 
was able to use its asset more efficiently than Novartis almost all the time. Besides that 
the two groups had to endure high risk arising from the different foreign currency 
exchange caused by cross-border sales, which cover with derivative assets. 
The impact of accounting policy can also remarkable in terms of profitability. If other 
expenditures of Richter would rise so far as by which more provisions are separated by 
the Novartis in a percentage of total asset compared to Richter, so the ROA of Richter 
would lower by 6% in average than otherwise in all the examined period (Figure 5). 
Although provisioning is accounted against profit, in fact, thereby Novartis can decrease 
its higher operating risk exposure – resulting from the uncertain outcome of researches – 
and to offset the Richter’s benefit resulting from its prudent financial policy. 
 
 
Figure 4: The calculation of return on assets (ROA) of Richter next to the provision ratio 
of Novartis 
Source: own compilation. 
4. Proposals and summary 
 
The Richter would able to decline its disadvantage against Novartis in terms of return of 
R&D investments with that if it corrects its investment policy: as Novartis, in addition to 
sales, also growing part of its research activities performs in states those provide grants 
by compensate the acquisition costs for instance in the USA. In that case it would sales 
its formulas developed in manufacturing technology of higher level next to lower producing 
costs and – partly due to the demand there that claims less discounts and has lower price 
sensitivity – higher price reduction benefit compared to its regional competitors. However, 
for this single or combined use of multiple Japanese management techniques already 
may be necessary for the majority of companies included in the consolidation. The formers 
cannot devoid harmonize of the ever-changing trends in the global pharma market and 
the external market risks arising from the acquisitions with the company strategy. As it 
can see above, the pharma R&D activity had considerable impact on the long-term firming 
both individually and in comparison: this is mostly also supported by amount of tax saving 
validated by the aid system and the lower return of research investments at Richter 
compare with its Swiss competitor. Beside the grants both producers provided for the 
coverage of the high operating risk arising from R&D and foreign currency exchange: as 
long as the Novartis enforces the principle of prudence in its accounting policy, the Richter 
does the same in its financial strategy. All in all, the leadership of two companies show 
0.00%2.00%4.00%6.00%8.00%10.00%12.00%14.00% 2009 2010 2011 2012 Original ROA beforetaxes at RichterModified ROA beforetaxes at RichterROA before taxes atNovartis
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maximum effort and diligence to promote the pharmaceutical researchers and by this to 
improve the overall public health situation of the regional and world population. 
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